Key facts
- Valo Therapeutics’s last known valuation is $24.3M (Mar 2021).
- It has raised $44.7M; the latest was Later Stage VC ($19.9M) in Mar 2025.
- Notable investors include CDP Venture Capital (Rome), Indaco Venture Partners, Enea Tech e Biomedical, University of Helsinki Endowment, Carlo Civelli — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Valo Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Valo Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Valo Therapeutics
Developer of immunotherapy treatments designed to improve cancer treatment and prevention. The company develops a peptide-based immunotherapy platform that combines oncolytic and non-replicating viral vectors with disease-specific peptides to stimulate targeted immune responses, enabling the development of adaptable cancer therapies with improved specificity and immunogenicity.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Founded
- 2016
- Employees
- 16
- Website
- valotx.com/
- Ownership
- Privately Held (backing)
Valo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.